Literature DB >> 18525425

Morphea profunda presenting as a neuromuscular mimic.

N C Voermans1, S Pillen, E M de Jong, M Cw Creemers, M Lammens, N van Alfen.   

Abstract

Localized scleroderma is characterized by idiopathic fibrosis of the skin and adjacent structures, and muscle involvement occurs predominantly in deep morphea. We report a patient with linear scleroderma who presented with slowly progressive atrophy, muscle weakness, and loss of function of her right arm, mimicking a neuromuscular disorder. Muscle biopsy eventually revealed zones of myositis, compatible with morphea profunda. Morphea profunda may thus present as a neuromuscular mimic, even in case of nonprogressive skin sclerosis. Myositis in morphea profunda is generally limited to one region, whereas inflammatory myopathies generally cause diffuse proximal muscle weakness and atrophy. Furthermore, skin changes in morphea profunda differ from those seen in dermatomyositis, and histological features of muscle biopsy can further distinguish between morphea profunda and inflammatory myopathies. Muscle biopsy in morphea profunda implies the risk of sampling error, whereas results of electromyography and muscle imaging might better represent the extent of muscle inflammation.

Entities:  

Mesh:

Year:  2008        PMID: 18525425     DOI: 10.1097/CND.0b013e318175c495

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  3 in total

Review 1.  Morphea and Eosinophilic Fasciitis: An Update.

Authors:  Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

2.  A cross-sectional electromyography assessment in linear scleroderma patients.

Authors:  Claudia Saad Magalhães; Taciana de Albuquerque Pedrosa Fernandes; Thiago Dias Fernandes; Luis Antonio de Lima Resende
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-12       Impact factor: 3.054

Review 3.  Diagnostic Value of Muscle Ultrasound for Myopathies and Myositis.

Authors:  Jemima Albayda; Nens van Alfen
Journal:  Curr Rheumatol Rep       Date:  2020-09-28       Impact factor: 4.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.